397 related articles for article (PubMed ID: 26659273)
41. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
42. Development and characterization of a bispecific single-chain antibody directed against T cells and ovarian carcinoma.
Kriangkum J; Xu B; Gervais C; Paquette D; Jacobs FA; Martin L; Suresh MR
Hybridoma; 2000 Feb; 19(1):33-41. PubMed ID: 10768839
[TBL] [Abstract][Full Text] [Related]
43. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.
Reusch U; Le Gall F; Hensel M; Moldenhauer G; Ho AD; Little M; Kipriyanov SM
Int J Cancer; 2004 Nov; 112(3):509-18. PubMed ID: 15382079
[TBL] [Abstract][Full Text] [Related]
44. The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.
Glorius P; Baerenwaldt A; Kellner C; Staudinger M; Dechant M; Stauch M; Beurskens FJ; Parren PW; Winkel JG; Valerius T; Humpe A; Repp R; Gramatzki M; Nimmerjahn F; Peipp M
Leukemia; 2013 Jan; 27(1):190-201. PubMed ID: 22660187
[TBL] [Abstract][Full Text] [Related]
45. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H
Cancer Res; 1997 May; 57(9):1704-9. PubMed ID: 9135012
[TBL] [Abstract][Full Text] [Related]
46. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma.
Moore PA; Zhang W; Rainey GJ; Burke S; Li H; Huang L; Gorlatov S; Veri MC; Aggarwal S; Yang Y; Shah K; Jin L; Zhang S; He L; Zhang T; Ciccarone V; Koenig S; Bonvini E; Johnson S
Blood; 2011 Apr; 117(17):4542-51. PubMed ID: 21300981
[TBL] [Abstract][Full Text] [Related]
47. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
48. A Recombinant Bispecific CD20×CD95 Antibody With Superior Activity Against Normal and Malignant B-cells.
Nalivaiko K; Hofmann M; Kober K; Teichweyde N; Krammer PH; Rammensee HG; Grosse-Hovest L; Jung G
Mol Ther; 2016 Feb; 24(2):298-305. PubMed ID: 26581163
[TBL] [Abstract][Full Text] [Related]
49. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
[TBL] [Abstract][Full Text] [Related]
50. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.
Bortoletto N; Scotet E; Myamoto Y; D'Oro U; Lanzavecchia A
Eur J Immunol; 2002 Nov; 32(11):3102-7. PubMed ID: 12385030
[TBL] [Abstract][Full Text] [Related]
51. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
52. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC
Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704
[TBL] [Abstract][Full Text] [Related]
53. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.
Stadler CR; Bähr-Mahmud H; Celik L; Hebich B; Roth AS; Roth RP; Karikó K; Türeci Ö; Sahin U
Nat Med; 2017 Jul; 23(7):815-817. PubMed ID: 28604701
[TBL] [Abstract][Full Text] [Related]
54. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
Ren-Heidenreich L; Davol PA; Kouttab NM; Elfenbein GJ; Lum LG
Cancer; 2004 Mar; 100(5):1095-103. PubMed ID: 14983507
[TBL] [Abstract][Full Text] [Related]
55. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
[TBL] [Abstract][Full Text] [Related]
56. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Crawford A; Haber L; Kelly MP; Vazzana K; Canova L; Ram P; Pawashe A; Finney J; Jalal S; Chiu D; Colleton CA; Garnova E; Makonnen S; Hickey C; Krueger P; DelFino F; Potocky T; Kuhnert J; Godin S; Retter MW; Duramad P; MacDonald D; Olson WC; Fairhurst J; Huang T; Martin J; Lin JC; Smith E; Thurston G; Kirshner JR
Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217340
[TBL] [Abstract][Full Text] [Related]
57. MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies.
Liu L; Lam CK; Long V; Widjaja L; Yang Y; Li H; Jin L; Burke S; Gorlatov S; Brown J; Alderson R; Lewis MD; Nordstrom JL; Koenig S; Moore PA; Johnson S; Bonvini E
Clin Cancer Res; 2017 Mar; 23(6):1506-1518. PubMed ID: 27663593
[No Abstract] [Full Text] [Related]
58. A bispecific single-chain antibody fusion protein for targeted depletion of autoreactive B cells via unstimulated human T lymphocytes.
Zocher M; Baeuerle PA
Mol Immunol; 2004 Jul; 41(5):511-8. PubMed ID: 15183929
[TBL] [Abstract][Full Text] [Related]
59. A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells.
Otz T; Grosse-Hovest L; Hofmann M; Rammensee HG; Jung G
Leukemia; 2009 Jan; 23(1):71-7. PubMed ID: 18830257
[TBL] [Abstract][Full Text] [Related]
60. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
Trinklein ND; Pham D; Schellenberger U; Buelow B; Boudreau A; Choudhry P; Clarke SC; Dang K; Harris KE; Iyer S; Jorgensen B; Pratap PP; Rangaswamy US; Ugamraj HS; Vafa O; Wiita AP; van Schooten W; Buelow R; Force Aldred S
MAbs; 2019; 11(4):639-652. PubMed ID: 30698484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]